Abstract
According to the latest update from CheckMate 227 Part 1, at 6 years' minimum follow-up, nivolumab combined with ipilimumab continues to outperform chemotherapy up front for advanced non-small cell lung cancer in terms of overall survival. Dual immune checkpoint inhibition induced greater tumor shrinkage, and these deep responses strongly correlated with long-term OS benefit.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
